newsfilter
← Latest News
GlobeNewswire·

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in Response to Continuously Emerging SARS-CoV-2 Variants